CRESCENT BIOPHARMA, INC. Capital Expenditures Incurred but Not yet Paid
CRESCENT BIOPHARMA, INC. (CBIO) reported Capital Expenditures Incurred but Not yet Paid of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-07-30
- CRESCENT BIOPHARMA, INC. capital expenditures incurred but not yet paid for the quarter ending 2025-12-31 was -$75.00K.
- CRESCENT BIOPHARMA, INC. capital expenditures incurred but not yet paid for the quarter ending 2025-09-30 was $31.00K.
- CRESCENT BIOPHARMA, INC. capital expenditures incurred but not yet paid for the quarter ending 2024-12-31 was $0.00.
- CRESCENT BIOPHARMA, INC. capital expenditures incurred but not yet paid for the quarter ending 2020-09-30 was $4.10K.
- CRESCENT BIOPHARMA, INC. capital expenditures incurred but not yet paid for fiscal 2025 was $11.00K.
- CRESCENT BIOPHARMA, INC. capital expenditures incurred but not yet paid for fiscal 2017 was $20.00K, a 6.07% decline from fiscal 2016.
- CRESCENT BIOPHARMA, INC. capital expenditures incurred but not yet paid for fiscal 2016 was $21.29K.
| Period end | Capital Expenditures Incurred but Not yet Paid 0 month | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-07-30 | ||||
| 2025-12-31 | -$75.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$44.00K derived: sum of 2 quarters · filed 2026-02-26 | $11.00K 10-K · filed 2026-02-26 | ||
| 2025-09-30 | $31.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $86.00K 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $55.00K 10-Q · filed 2026-07-30 | ||||
| 2024-12-31 | $0.00 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-06 | ||||
| 2020-09-30 | $4.10K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $10.69K 10-Q · filed 2021-11-02 | |||
| 2020-06-30 | $6.59K 10-Q · filed 2021-08-05 | ||||
| 2019-03-31 | $35.92K 10-Q · filed 2020-05-01 | ||||
| 2017-12-31 | $20.00K 10-K · filed 2020-02-28 | ||||
| 2017-03-31 | $9.55K 10-Q · filed 2018-05-03 | $1.52K derived: sum of 2 quarters · filed 2019-03-06 | $10.55K derived: sum of 3 quarters · filed 2019-03-06 | ||
| 2016-12-31 | -$8.04K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-06 | $995.00 derived: sum of 2 quarters · filed 2019-03-06 | $21.29K 10-K · filed 2019-03-06 | ||
| 2016-09-30 | $9.03K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $29.33K 10-Q · filed 2017-11-08 | |||
| 2016-06-30 | $20.30K 10-Q · filed 2017-08-03 | ||||
| 2015-06-30 | $464.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $10.46K 10-Q · filed 2016-08-04 | |||
| 2015-03-31 | $10.00K 10-Q · filed 2016-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |